GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Intermediate-1 Risk1–1
- Intermediate-2 Risk2–2
- High Risk3–6
The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include karyotype risk. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.
Clinical Indication
The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis is indicated for bedside clinical practice to support The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
GIPSS Score = Karyotype Risk Points + CALR Type 1 Absence Points + ASXL1 Mutation Points + SRSF2 Mutation Points + U2AF1Q157 Mutation Points, where total score ranges from 0-6 points
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| karyotype_risk | string | Yes | Cytogenetic risk classification based on karyotype analysis |
| calr_type1_mutation | string | Yes | Presence of type 1/like CALR (calreticulin) mutation |
| asxl1_mutation | string | Yes | Presence of ASXL1 (Additional Sex Combs-Like 1) mutation |
| srsf2_mutation | string | Yes | Presence of SRSF2 (Serine/Arginine-Rich Splicing Factor 2) mutation |
| u2af1q157_mutation | string | Yes | Presence of U2AF1Q157 (U2 Small Nuclear RNA Auxiliary Factor 1) mutation |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Excellent prognosis |
| 1–1 | Intermediate-1 Risk | Good prognosis |
| 2–2 | Intermediate-2 Risk | Intermediate prognosis |
| 3–6 | High Risk | Poor prognosis |
Evidence-Based References (EBM)
- Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z.DOI: 10.1038/s41375-018-0107-z
- Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.DOI: 10.1038/leu.2017.169
- Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318. doi: 10.1200/JCO.2017.76.4886.DOI: 10.1200/JCO.2017.76.4886